🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Recruitingn/aAges 18 Years - anyAllIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT06767254 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Signed Informed Consent form for study participation and personal data processing * Diagnosis of active multiple myeloma Exclusion Criteria: * None
💊

What it tests

  • Not listed
📍

Where

4 sites
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
ARNAS "G. Brotzu" di Cagliari
Cagliari, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy